Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
KYN-5356 by Kynexis Therapeutics for Cognitive Impairment Associated With Schizophrenia (CIAS): Likelihood of Approval
KYN-5356 is under clinical development by Kynexis Therapeutics and currently in Phase I for Cognitive Impairment Associated With Schizophrenia (CIAS)....